Robatumumab
- Product Name
- Robatumumab
- CAS No.
- 934235-44-6
- Chemical Name
- Robatumumab
- Synonyms
- Robatumumab;Robatumumab (anti-IGF1R);Research Grade Robatumumab;Research Grade Robatumumab(DHC29906)
- CBNumber
- CB68080798
- Formula Weight
- 0
- MOL File
- Mol file
Robatumumab Property
- form
- Liquid
- color
- Colorless to light yellow
Robatumumab Chemical Properties,Usage,Production
Uses
Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research[1][2].
in vivo
Robatumumab (intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 d) inhibits the SK-N-FI tumor growth in xenograft model[2].
Robatumumab (intravenous injection; 0.02-0.5 mg/mouse; twice weekly; 35 d) inhibits the osteosarcoma growth in xenograft model[2].
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 d) inhibits the SJCRH30 and RD rhabdomyosarcoma cell growth in xenograft model[2].
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 w) blocks effectively pediatric tumor cell proliferation in vivo[2].
Robatumumab (intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation) modulates the blood vessel formation via its antiangiogenesis effect[2].
| Animal Model: | Nude mice inoculated with SK-N-FI tumor cells[2] |
| Dosage: | 0.04 or 0.1 mg/mouse |
| Administration: | Intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 days |
| Result: | Inhibited the SK-N-FI xenograft tumor by 96% in the 0.04 mg dose group and resulted in 11% tumor regression in the 0.1 mg dose group. |
| Animal Model: | Nude mice inoculated with SJSA-1 osteosarcoma[2] |
| Dosage: | 0.02, 0.1 or 0.5 mg/mouse |
| Administration: | Intravenous injection; 0.02, 0.1 or 0.5 mg/mouse; twice weekly; 35 days |
| Result: | Inhibited the tumor growth by 71%, 82%, and 88% at 0.02, 0.1, and 0.5 mg, respectively, at day 14 after treatment. |
| Animal Model: | Nude mice inoculated with SJCRH30 and RD rhabdomyosarcoma cells[2] |
| Dosage: | 0.1 or 0.5 mg/mouse |
| Administration: | Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 days |
| Result: | Inhibited tumor growth by 39% and 58% at 0.1 and 0.5 mg dose, respectively, in the RD rhabdomyosarcoma model. Inhibited tumor growth by 37% and 53% at 0.1 and 1 mg dose, respectively, in the SJCRH30 model. |
| Animal Model: | Nude mice inoculated with SK-N-FI neuroblastoma and SJSA-1 osteosarcoma[2] |
| Dosage: | 0.1 or 0.5 mg/mouse |
| Administration: | Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 weeks |
| Result: | Reduced the tumor Ki-67 staining by 38% and along with significant change in SK-N-FI neuroblastoma xenograft. Reduced the staining of Ki-67 by 37% and 51% after 0.1 and 0.5 mg SCH 717454 treatment, respectively, in the SJSA-1 osteosarcoma xenograft. |
| Animal Model: | Nude mice inoculated with SJSA-1 osteosarcoma[2] |
| Dosage: | 0.5 mg/mouse |
| Administration: | Intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation |
| Result: | Reduced in the intensity of the fluorescent lectin staining by 74% at 0.5 mg dose, showing thinner blood vessels and reduced branches, compared with control IgG1. |
References
[1] Anderson PM, et al. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. Pediatr Blood Cancer. 2016 Oct;63(10):1761-70. DOI:10.1002/pbc.26087
[2] Wang Y, et al. A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts. Mol Cancer Ther. 2010 Feb;9(2):410-8. DOI:10.1158/1535-7163.MCT-09-0555
Robatumumab Preparation Products And Raw materials
Raw materials
Preparation Products
Robatumumab Suppliers
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ：422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24961
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 021-59167510 18117107507
- vip@med-life.cn
- Country
- China
- ProdList
- 5002
- Advantage
- 58
- Tel
- 0731-13823398 15111215862
- 313359644@qq.com
- Country
- China
- ProdList
- 4161
- Advantage
- 58